Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
obesity, Risks and Ozempic and Mounjaro
Ozempic: Landmark study unveils risk and benefits of popular obesity drug
Debate over the risks and benefits of the population weight loss drugs like Ozempic, Wegovy, and Zepbound finally came to an end after a new landmark study.According to Global News, a new observational study published in the journal
Landmark Study Reveals New Benefits and Risks of Obesity Drugs Like Ozempic
A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss.
Obesity drugs: huge study highlights new health risks
Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.
Ozempic-style drugs tied to more than 60 health benefits and risks in biggest study-of-its-kind
A large new study has shed light on the wider health impacts of taking Ozempic-style drugs. Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of experiencing 19 others, according to one of the most comprehensive studies-of-its-kind to date.
The Health Risks and Benefits of Weight-Loss Drugs
The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight.In report published in Nature Medicine,
Weight-loss drugs linked to benefits beyond dropping pounds
A new study published in the Nature Medicine monthly journal highlights the benefits and risks of weight-loss drugs like Ozempic and Wegovy. Positives include reduced risks of infections and cardiac arrest,
Researchers reveal benefits, risks linked to popular weight-loss drugs
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,
Weight loss drugs reduce risk for medical conditions and diseases, study shows
Researchers studied medical records of veterans who have diabetes. Prince Harry settles lawsuit with Murdoch papers after apology How To Invest In The S&P 500 (Step By Step) The Star Player Being Kept Out of Cooperstown by a Trash Can What the 14th Amendment says about birthright citizenship 10 Reliable Luxury Cars That Will Last You A Lifetime China's 'artificial sun' shatters nuclear fusion record by generating steady loop of plasma for 1,
Weight-loss drugs linked to unexpected benefits and risks
The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks of addiction.
1d
on MSN
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
New Scientist on MSN
19h
GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...
1h
on MSN
Scientists say drugs like Ozempic and Wegovy 'could slash risk of 42 health conditions'
Researchers took drugs currently used to treat type 2 diabetes and obesity and looked into how they affect 175 conditions.
21h
on MSN
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
8h
on MSN
See ya, knock-off Ozempic
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
2d
on MSN
Ozempic May Damage Vital Organs, Study Finds
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
1d
on MSN
The race for the next Ozempic is on
Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...
3d
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
4d
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback